Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Reference is made to the stock exchange announcement made by SalMar ASA ("SalMar" or the "Company") on 25 August 2026 of the launch of SalMar’s share buyback program to purchase up to 100,000 of the Company's shares for a total amount of up to NOK 65 million during the period from 25 August 2026, until no later than 30 September 2026, pursuant to an agreement with DNB Carnegie, a part of DNB Bank ASA. SalMar has now completed the share buyback program. A total of 100,000 shares, which equals 0.0
For the complete transcript of the earnings call, please refer to the full earnings call transcript. Record strong biological performance with mortality 40% lower, growth 33% higher, and superior share 9 percentage points higher than the 10-year average. Acquisition of Msval expected to generate annual operational cost synergies of approximately NOK300 million.
Strong operational and biological performance in Norway resulted in a record-high harvest volume for a second quarter and a significant improvement in earnings compared with the same period last year. Higher volumes, improved fish quality, and lower costs throughout the value chain contributed positively, while an unfavourable harvest profile, with the majority of volumes harvested in June, negatively impacted price achievement during the period. Operational EBIT for the Group amounted to NOK 1,
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.